Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 8 - Jul 13
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
Wegovy vs Ozempic vs Zepbound: Which weight loss injection is right for YOU? Swipe left to compare! Zepbound = NEW & strongest (20%+ weight loss) Ozempic = Cheaper but GLP 1 is changing taste: How can food makers reignite flavour? can i drink coke zero on semaglutide Amazon.com : Coca Cola Coke Zero Sugar Diet Soda, Best Semaglutide Orange County & Beverly Hills Michael Yoo MD
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
4.8 ★★★★★
Based on 818 reviews
Sort
Product Reviews
★★★★★ 1
No casebook connect
Format: Hardcover, Format: Hardcover
I ordered a new print version of the textbook to specifically receive the casebook connect code. The book also came wrapped, but when I undid the wrapping and opened the textbook, there was no code. It looks like somebody peeled the code information away as the cover has some yellowing, which I imagine is due to glue residue. I’m incredibly disappointed and now I need to purchase the code in addition to the $220 I spent on this textbook.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on January 18, 2023
★★★★★ 2
Readable
Format: Hardcover, Format: Hardcover
Not at all what I would consider “Very Good” condition, as the book was described. Pretty disappointed to be honest, considering I paid over $100 for this. It’s beaten up, torn, and dirty, but it’s readable.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on September 18, 2021
★★★★★ 1
Not as listed!
Format: Hardcover
I paid nearly 300 dollars for this book and it was not as listed. I bought this because it was listed as new, but the book arrived with a broken binding, highlighting and writing throughout the pages, and the course ecode was already used. Unfortunately, I cannot use it for my studies.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on January 13, 2022
★★★★★ 5
Coverage lined up nearly perfectly with my fed courts class
Format: Paperback
Almost every case we covered in class and definitely every concept is covered, and explained helpfully, in this E&E. The problems are helpful, too.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 15, 2021
★★★★★ 5
Great Federal Courts supplement
Format: Paperback
This E&E book really helped with Fed. Courts! Incorporate the public v. private law models/SOP and federalist v. nationalist paradigms which my professor used in the course. This version doesn't have some of the newer cases (TransUnion v. Ramirez). The standing section could have more info but standing is one of the easiest doctrines in fed courts. The Habeas Corpus, particularly the Teague Doctrine and AEDPA, section is excellent. The only big thing this book does not include are universal injunctions and the scope of remedies (outside of standing, anti-injunction act, and section 1983).
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 5, 2025
recommand products
GLP-1RA and thyroid cancer: New study suggests detection bias, not causation
23.45
Both GLP-1 Receptor Agonists and Bariatric Surgery Lower the Risk of Weight-Related Cancer in Patients With Obesity
21.48
GLP-1s tied to lower risk for 10 types of cancer compared with insulin in type 2 diabetes
25.65
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer | Cancer and Metastasis Reviews
26.11
GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology's annual meeting
24.60